Lantern Pharma Inc (LTRN) Stock Price, Quote & News

Company Profile

Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 277 1136

Website: www.lanternpharma.com

Address:

1920 McKinney Avenue, 7th Floor, Dallas, United States

Stock_Catcher Jan. 20 at 1:04 PM

$LTRN LTRN Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

0 · Reply

Bulltrader988 Jan. 15 at 10:01 PM

$LTRN Forming...nice breakout 👃👀 https://finviz.com/quote.ashx?t=LTRN&ty=c&ta=1&p=d

0 · Reply

BioTuesdays Jan. 12 at 3:36 PM

$LTRN has announced the establishment of the AI Center of Excellence and Advanced Agentic Labs in Bengaluru, India, to industrialize its proprietary RADR AI platform, which integrates hundreds of billions of data points to identify biomarkers, predict drug response, and design smarter clinical trials https://biotuesdays.com/2026/01/12/lantern-launches-ai-center-in-india-to-industrialize-radr/

0 · Reply

Bulltrader988 Jan. 12 at 2:20 PM

$LTRN 👃👀 https://www.stocktitan.net/news/LTRN/lantern-pharma-announces-establishing-an-a-i-center-of-excellence-in-qowogkxoafpo.html

0 · Reply

DARKP00L Jan. 12 at 2:20 PM

$LTRN 09:10 on Jan. 12 2026 Lantern Pharma Announces Establishment Of A.I. Center Of Excellence And Advanced Agentic Labs In Bengaluru, India #tradeideas

0 · Reply

AAKSHI9953 Jan. 6 at 4:09 PM

$LTRN Does this company is still in business?

0 · Reply

OfficialStocktwitsUser Dec. 31 at 9:49 PM

$LTRN RSI: 29.10, MACD: -0.1106 Vol: 0.26, MA20: 3.49, MA50: 3.56 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

SuperGreenToday Dec. 30 at 2:58 PM

$LTRN Share Price: $3.41 Contract Selected: Jul 17, 2026 $4.0 Calls Buy Zone: $0.88 – $1.09 Target Zone: $1.42 – $1.74 Potential Upside: 53% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

MicroscopeMaster Dec. 26 at 12:58 PM

$LTRN Expectations are recalibrating toward pragmatic delivery instead of lofty projections. Cash efficiency must trend upward while maintaining strategic flexibility. Risk compresses once delivery patterns become predictable. The trajectory strengthens as results compound visibly.

0 · Reply

DailyDigestDave Dec. 24 at 10:59 AM

$LTRN The longer-term setup revolves around whether measurable traction replaces episodic catalyst-driven interest. Clear inflection points are required to justify renewed interest.

0 · Reply

Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies

Dec 3, 2025, 8:35 AM EST - 6 weeks ago

Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials

Nov 20, 2025, 8:33 PM EST - 2 months ago

Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript

Nov 13, 2025, 1:11 PM EST - 2 months ago

Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 8:30 AM EST - 2 months ago

Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 6, 2025, 8:00 AM EST - 2 months ago

Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET

Oct 30, 2025, 8:00 AM EDT - 2 months ago

Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT

Oct 28, 2025, 8:49 AM EDT - 3 months ago

Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.

Oct 24, 2025, 8:00 AM EDT - 3 months ago

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025

Sep 16, 2025, 8:29 AM EDT - 4 months ago

Lantern Pharma's LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors

Sep 10, 2025, 8:00 AM EDT - 4 months ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)

Sep 3, 2025, 9:44 AM EDT - 4 months ago

Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial

Aug 13, 2025, 4:30 PM EDT - 5 months ago

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

Aug 6, 2025, 8:30 AM EDT - 5 months ago

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

Aug 4, 2025, 8:55 AM EDT - 6 months ago

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

Jul 31, 2025, 7:30 AM EDT - 6 months ago

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

Jul 28, 2025, 8:00 AM EDT - 6 months ago

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

Jul 23, 2025, 7:56 AM EDT - 6 months ago

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

Jul 21, 2025, 8:20 AM EDT - 6 months ago

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

Jul 15, 2025, 9:40 AM EDT - 6 months ago

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

Jun 16, 2025, 8:30 AM EDT - 7 months ago

Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

May 29, 2025, 8:30 AM EDT - 8 months ago

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

May 15, 2025, 3:04 PM EDT - 8 months ago

Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript

May 15, 2025, 8:45 AM EDT - 8 months ago

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

May 12, 2025, 9:00 AM EDT - 9 months ago

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

May 8, 2025, 8:30 AM EDT - 9 months ago

Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

May 5, 2025, 8:55 AM EDT - 9 months ago

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

Mar 27, 2025, 8:35 PM EDT - 10 months ago

Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:01 PM EDT - 10 months ago

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Mar 20, 2025, 8:00 AM EDT - 10 months ago

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

Feb 19, 2025, 8:00 AM EST - 11 months ago

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Jan 27, 2025, 7:55 AM EST - 1 year ago

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

Dec 9, 2024, 8:15 AM EST - 1 year ago

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Dec 3, 2024, 8:00 AM EST - 1 year ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Nov 26, 2024, 8:45 AM EST - 1 year ago

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Nov 19, 2024, 8:00 AM EST - 1 year ago

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Nov 8, 2024, 7:23 PM EST - 1 year ago

Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 1 year ago

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Nov 5, 2024, 8:00 AM EST - 1 year ago

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Oct 23, 2024, 8:45 AM EDT - 1 year ago

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Oct 21, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma to Host & Participate in Two Public Webinars During October

Oct 15, 2024, 9:07 AM EDT - 1 year ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers

Aug 10, 2024, 4:01 AM EDT - 1 year ago

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Aug 7, 2024, 9:31 AM EDT - 1 year ago

Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET

Jul 10, 2024, 8:30 AM EDT - 1 year ago

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Stock_Catcher Jan. 20 at 1:04 PM

$LTRN LTRN Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

0 · Reply

Bulltrader988 Jan. 15 at 10:01 PM

$LTRN Forming...nice breakout 👃👀 https://finviz.com/quote.ashx?t=LTRN&ty=c&ta=1&p=d

0 · Reply

BioTuesdays Jan. 12 at 3:36 PM

0 · Reply

Bulltrader988 Jan. 12 at 2:20 PM

$LTRN 👃👀 https://www.stocktitan.net/news/LTRN/lantern-pharma-announces-establishing-an-a-i-center-of-excellence-in-qowogkxoafpo.html

0 · Reply

DARKP00L Jan. 12 at 2:20 PM

$LTRN 09:10 on Jan. 12 2026 Lantern Pharma Announces Establishment Of A.I. Center Of Excellence And Advanced Agentic Labs In Bengaluru, India #tradeideas

0 · Reply

AAKSHI9953 Jan. 6 at 4:09 PM

$LTRN Does this company is still in business?

0 · Reply

OfficialStocktwitsUser Dec. 31 at 9:49 PM

0 · Reply

SuperGreenToday Dec. 30 at 2:58 PM

0 · Reply

MicroscopeMaster Dec. 26 at 12:58 PM

0 · Reply

DailyDigestDave Dec. 24 at 10:59 AM

$LTRN The longer-term setup revolves around whether measurable traction replaces episodic catalyst-driven interest. Clear inflection points are required to justify renewed interest.

0 · Reply

OfficialStocktwitsUser Dec. 23 at 5:47 PM

$LTRN RSI: 49.14, MACD: -0.0630 Vol: 0.22, MA20: 3.58, MA50: 3.66 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

judgeyoung2 Dec. 20 at 12:21 AM

$LTRN do we still expect data this month?

1 · Reply

NetworkNewsWire Dec. 3 at 5:53 PM

BioMedNewsBreaks – $LTRN Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors https://ibn.fm/ggRuI

0 · Reply

AlbertSan Dec. 3 at 2:40 PM

$LTRN new here with 700 shares! 🤞

0 · Reply

TradesWolf Dec. 3 at 2:07 PM

$LTRN great news

0 · Reply

Bulltrader988 Dec. 3 at 2:00 PM

$LTRN 👃👀 https://www.stocktitan.net/news/LTRN/lantern-pharma-reports-additional-positive-lp-184-phase-1a-results-akqengm84vik.html

0 · Reply

OpenOutcrier Dec. 3 at 1:54 PM

$LTRN (+9.5% pre) Lantern Pharma reports positive LP-184 phase 1a cancer trial results https://ooc.bz/l/86125

0 · Reply

MrTicker Dec. 3 at 1:41 PM

$LTRN BRIEF-Lantern Pharma Reports Additional Positive Lp-184 Phase 1A Results Showing Durable Disease Control In Heavily Pre-Treated Advanced Cancer Patients REUTERS 7:41 AM ET 12/3/2025

0 · Reply

MrTicker Dec. 3 at 1:37 PM

$LTRN Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials BUSINESS WIRE 7:35 AM ET 12/3/2025

0 · Reply

Stock_Catcher Dec. 3 at 1:35 PM

0 · Reply

Market Cap	38.25M
Revenue (ttm)	0.00
Net Income (ttm)	-20.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	106,976
Avg Vol	63,812
Day's Range	N/A - N/A
Shares Out	11.18M
Stochastic %K	52%
Beta	1.58
Analysts	Strong Sell
Price Target	$25.00